Abstract: The present invention relates to compounds of formula I 1

Abstract: Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems: 1

Abstract: The invention provides compounds of formula 1 1

Abstract: The invention provides compounds of formula 1 1

Abstract: The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission.

Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder such as pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction, using a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described.

Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder such as pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction. using a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides compounds of formula 1 1

Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder, such as pathological gambling, attention deficit disorder with hyperactivity disorder and sex addiction, comprising administering a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.

Abstract: Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems: 1

Abstract: Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems: 1

Abstract: The invention provides compounds of formula 1 1

Abstract: The invention provides compounds of formula 1 1

Abstract: The present invention relates to a method of treating dementia or cognitive deficits associated with Alzheimer's Disease or Parkinson's Disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor in combination with an acetylcholine esterase inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 dopamine receptor and an acetylcholine esterase inhibitor.

Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder such as pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction. using a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.

Abstract: Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems:

Abstract: An ink replenishment system for supplying a working solution of an ink to an electrographic imaging device. A plurality of removable ink cartridges each have at least a first compartment containing ink concentrate and a second compartment. A fluid handling system couples the first compartment of each ink cartridge to a respective working solution reservoir. A controller controls the flow of ink concentrate from each ink cartridge and liquid carrier from a source of liquid carrier to maintain a working solution concentration of working solution in each of the working solution reservoirs. A return system fluidly couples each of the developer stations to the second compartment of the respective ink cartridges. Alternate embodiments include one compartment and three compartment cartridges, and locating the working solution reservoir in the removable cartridge.

Abstract: An ink cartridge for use in an ink replenishment system in an electrographic imaging device. The removable ink cartridge is configured to engage with a cartridge interface assembly and a detector in an ink cartridge bay on an electrographic imaging device. The ink cartridge has an outer shell comprising at least a first compartment containing a liquid ink and a second compartment. A first valve is fluidly coupled to the first compartment. Second and third valves are fluidly coupled to the second compartment. The first, second, and third valves are adapted to engage with corresponding valves at the cartridge interface assembly. A plurality of key slots are provided for receiving one or more key tabs that identify the ink cartridge. The key tabs are positioned to engage with the detector in the ink cartridge bay. A cap for an ink cartridge is also disclosed.

Abstract: Pharmaceutically active benzimidazole derivatives are disclosed comprising compounds of the formula: ##STR1## particularly wherein X is nitrogen, R.sup.1 is phenyl or heteroaryl, and one of R.sup.2 or R.sup.3 is hydroxy.